Combination immunogene therapy
AssigneeAMDL, Inc.
InventorLung-Ji Chang
Life of this patent
Estimating the term…
Abstract
The present invention provides to immunogene therapy protocols for the treatment of tumors. In particular, the present invention provides combinations of immune-modulating proteins that induce systemic immunity against tumors. In addition, the present invention provides humanized animal models suitable for the evaluation of anti-human tumor immunity and permit the identification of combinations of immune-modulating genes which when delivered to human tumor cells induce an effective anti-tumor response, including a systemic anti-tumor response.
Claims16
An immunodeficient mouse comprising:
- a) human T lymphocytes expressing the CD45 antigen, wherein at least 5% of the human T cells expressing the CD45 antigen represent immature naive T lymphocytes;
- and
- b) human tumor cells;
- wherein said immunodeficient mouse is a SCID/beige mouse.
A tumor cell vaccine comprising a tumor cell expressing B7-2 and at least one additional immune modulator.
A method of treating a tumor comprising:
- a) providing:
- i) a subject having a tumor of the central nervous system;
- ii) an expression vector encoding the human B7-2 protein and at least one additional immune modulator;
- b) transferring said expression vector into said tumor under conditions such that said B7-2 protein and said immune-modulator are expressed by at least a portion of said tumor.
Dependencies are inferred from the claim text.